AUSTIN, TX / ACCESS Newswire / March 2, 2026 / In modern metabolic medicine, few treatments have reshaped care like GLP-1 receptor agonists. If you are asking what is semaglutide, it is a prescription ...

Today, in the second part of this unmissable series, we'll see how making changes to our daily food choices and sleeping ...

Nearly 1 in 5 women 65+ have been diagnosed with diabetes. Experts urge screening and simple prevention steps.

Novo Nordisk NVO has endured a brutal week, with its shares plunging 21% after a series of disappointing clinical results and mounting pricing pressures erased virtually all the gains accumulated ...

Background People living with HIV (PWH) are at increased risk of cardiovascular disease; however, evidence from Asian populations remains limited. We evaluated the prevalence and characteristics of ...

Biomea Fusion (NASDAQ:BMEA) outlined progress on its clinical-stage pipeline during an Oppenheimer virtual conference ...

VTVT stock outlook: underfollowed T1D catalyst with Phase 3 CATT1 cadisegliatin data due 2H2026, improved timeline and runway ...

New American Red Cross data reveals that 1 in 5 blood donors have elevated A1C levels — a sign that prediabetes and diabetes are prevalent among adults in generally good health.

Investing.com -- Eli Lilly and Co (NYSE:LLY) announced Thursday that its oral GLP-1 drug orforglipron delivered superior blood sugar control and weight loss compared to oral semaglutide in a Type 2 ...

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases ...

Agreement provides additional funding tool of up to $25 million over a period of up to 36 months - Underpins the Company's ambitions to expand its commercialisation activities and advance its innovati ...

Our Real Talk with a Doc columnist explains how to push back if your doctor's obsessed with weight loss. And what other health metrics matter more instead.